Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photoallergy Potential of Dapsone Gel
NCT02117739Phase 1Completed
- Sponsor
- Almirall
- Start
- Apr 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, double-blind, single-arm trial of dapsone in acne vulgaris, sponsored by Almirall. Primary endpoint: Photoallergic (Sensitizing) Potential Using a Visual Scale at Week 6. Started Apr 2014; status: completed.
02
Drugs
dapsone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02117739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117739.